| |
Group UnCh (N=142)
|
Group InCr (N=34)
|
Group DeCr (N=173)
|
All (N=349)
|
P-value*
|
|---|
|
Age
|
58 (16–83)
|
56 (25–83)
|
57 (18–84)
|
58 (16–84)
|
0.96
|
|
Gender (% women)
|
62
|
56
|
68
|
64
|
0.33**
|
|
Disease duration (months)
|
6.0 (1–13)
|
3.5 (1–12)
|
6.0 (1–21)
|
6,0 (1–21)
|
0.10
|
|
DAS28
|
5.4 (0.5-7.9)
|
5.5 (0.5-8.0)
|
5.1 (2.3-8.1)
|
5,3 (0,5-8,1)
|
0.06
|
|
HAQ
|
0.9 (0–2.6)
|
1.3 (0–2.3)
|
0.9 (0–2.5)
|
0,9 (0–2,6)
|
0.10
|
|
ESR (mm/H)
|
33 (2–110)
|
42 (2–140)
|
27 (2–115)
|
31 (2–140)
|
0.006
|
|
CRP (mg/L)
|
22.0 (4–186)
|
29.5 (3–159)
|
19.0 (4–228)
|
21 (3–228)
|
0.40
|
|
RF positive (%)
|
61
|
67
|
56
|
59
|
0.46**
|
|
Anti-CCP (%)
|
58
|
61
|
56
|
57
|
0.86**
|
|
COMP (U/L)
|
11.9 (6.1-26.8)
|
9.6 (5.6-19.3)
|
13.8 (4.5-32.0)
|
12.7 (4.5-32.0)
|
<0.001
|
|
Erosion score
|
0 (0–44)
|
0 (0–20)
|
0 (0–15)
|
0 (0–44)
|
0.68
|
|
JSN score
|
0 (0–40)
|
0 (0–15)
|
0 (0–33)
|
0 (0–40)
|
0.41
|
|
Total Sharp score
|
1 (0–84)
|
2 (0–34)
|
0.25 (0–35)
|
1 (0–84)
|
0.52
|
- Group UnCh, patients with unchanged serum-COMP levels from inclusion to 3 months follow-up (change ≤ 20%),
- Group InCr, increasing serum- COMP levels from inclusion to 3 months follow-up (increase > 20%).
- Group DeCr, decreasing serum-COMP levels from inclusion to 3 months follow-up (decrease > 20%).
- *Kruskal-Wallis test, ** Chi2 test.
